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tantly, we also demonstrate that insulin blunts release of MMP1 and
MMP13 protein into the culture media, counteracting the effect of
TNFa and IL-1b. Thus, insulin appears to play a selective protective
role in the diarthrodial joint by suppressing release of catabolic
enzymes into the synovial ﬂuid via its effects on FLSs. Further study
is needed to determine if insulin resistance in obesity/diabetes
impairs this critical role for insulin in protecting cartilage matrix in
synovial joints. Although the mechanism of selective suppression of
MMP1 and MMP13 by insulin is still unknown, insulin and insulin-
sensitizing agents could be new disease-modifying interventions in
OA treatment.
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Purpose: IL-17 and IL-22 are inﬂammatory cytokines classically
involved in chronic inﬂammation in various diseases. Here, we inves-
tigated the expression and the release of IL-17 and IL-22 by OA synovial
membranes, in relation to the inﬂammatory status of synovium.
Methods: Synovial membranes from OA knee patients (n ¼ 32) were
collected at surgery and inﬂammatory (Inﬂ) and non-inﬂammatory (NI)
areas were separated according to the macroscopic evaluation of
inﬂammation that appeared as hypervascularized areas with hyper-
trophic and hyperaemic villi. A piece of each tissuewas frozen for mRNA
extraction, ﬁxed in paraformaldehyde for histology and incubated in
serum free culture medium in order to obtain conditioned media con-
taining soluble factors released by synovial tissues. IL-1b, IL-6, IL-8, IL-
18, IL-17, IL-22, IL-23, TNF-a, TGF-b1, myeloperoxidase (MPO) andMMP-
9were analyzed for mRNA expression by quantitative RT-PCR and/or for
protein level by ELISA and gelatin zymography. Immunohistochemistry
for endothelial cells (CD31) and leukocytes (CD45) among them mac-
rophages (CD68), neutrophils (CD15) and T- and B-lymphocytes (CD3
and CD20, respectively) was performed.
Results: Inﬂammatory areas of OA synovial membranes were charac-
terized by increased CD45þ inﬂammatory cell inﬁltration and vessel
area/tissue area as compared to non-inﬂammatory areas (p¼ 0.001 and
p ¼ 0.009, respectively). Macrophages were present in the intimal layer
of both NI and Inﬂ OA synovial membranes with higher accumulation in
Inﬂ as compared to NI. Only the subintimal layer of Inﬂ areas of OA
synovial membranes contained macrophages, T- and B-lymphocytes
and some neutrophils. Consistently, the inﬂammatory markers MMP-9
and MPO were released in signiﬁcantly higher concentrations by Inﬂ
than by NI areas (p ¼ 0.026 and p ¼ 0.001, respectively). IL-17 and IL-22
were both expressed and released by OA synovial membranes. A
stronger mRNA expression was found in Inﬂ for both IL-17 and IL-22.
Inﬂ also released signiﬁcantly higher levels of IL-22 than NI (p ¼ 0.046).
Strong positive correlations were found between IL-17 and IL-22 at
mRNA and protein levels. The expression of IL-17 and IL-22 is controlled
by a subset of cytokines, including IL-1b, IL-6, IL-8, IL-18, IL-23, TGFb-1
and TNF-a. With the exception of TNF-a, all were released in sig-
niﬁcantly higher concentration by Inﬂ as compared to NI areas. IL-12
was not detected in conditioned media of synovial tissues.
Conclusions: Our results show an increased inﬁltration of lymphocytes
as well as an increased release of inﬂammatory cytokines, including IL-Synovial gene expression at day 1 after transection (as fold-change compared to healt
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Our results support a role for of the immune system in the patho-
physiology of OA. This study will be helpful to identify new therapeutic
strategies for OA leading to decrease inﬂammation.
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Purpose: Complement activation has been described as a patho-
mechanism of osteoarthritis (OA). It features an abnormally high
expression of complement activator genes (i.e. complement C1q, C4
and C2 on the classical pathway of activation and complement
factor B and D on the alternative pathway; encoded by C1QA, C1QB,
C1QC, C4A, C2, CFB and CFD) in synovial membranes of affected
patients. Both pathways lead to complement C3 (C3) activation and
deposition of membrane attack complex (MAC, consisting of com-
plement components C5b-C9, encoded by C5, C6, C7, C8A, C8B, C8G
and C9) on chondrocytes, affecting their gene expression (i.e.
expression of matrix metalloproteinases). Complement mediated OA
was observed in mouse models of meniscectomy. However, the role
of complement activation after ACL injury, a promising model for
posttraumatic OA, is unclear. The aim of this study was to inves-
tigate if ACL injury models of OA feature complement activation and
therefore are suited to test complement-targeting disease modifying
interventions. Speciﬁcally, we assessed the changes in gene
expression of complement effectors and inhibitors, which are eli-
cited in the synovial membranes early after ACL transection in a
porcine model.
Methods: 24 adolescent Yucatan minipigs received unilateral ACL
transection after IACUC approval. Synovial tissue was collected after
1, 5, 9 and 14 days (each n ¼ 6). Whole transcriptome sequencing
was used to quantify mRNA expression in the synovium. In order to
control for injury-related changes in gene expression, healthy control
tissue was obtained from 6 additional untreated animals (n ¼ 12).
Individual cDNA libraries were constructed with Illumina TruSeq Kit,
multiplexed (8 per lane) and sequenced on multiple lanes of an
Illumina HiSeq 2000. Raw reads were mapped to the pig genome
(Susscr3) and differential gene expression was calculated with the
edgeR subroutine package.
Results: mRNA expression of most complement activators, MAC
components and their inhibitors was signiﬁcantly upregulated 1 day
after ACL transection. However, they returned to control levels
within 14 days. Speciﬁcally, the expression of all assessed classical
pathway activators, as well as the classical pathway inhibitors
Plasma protease C1 inhibitor (SERPING1) and C4b-binding protein
(C4BPA) was signiﬁcantly increased at day 1 (see table). The
increased expression of almost all classical pathway activators and
inhibitors returned to control levels within 5 days post-transection.
Expression of the alternative pathway activator CFD was signiﬁcantly
elevated at all observed time points (11.1, 7.6, 5.3 and 22.2-fold for
day 1, 5, 9 and 14, p ¼ 5.05E-18, 6.74E-11, 9.10E-09 and 1.52E-18,
respectively), while the expression of the inhibitor complement
factor H (encoded by CFH) was increased 1, 5 and 9 days post-
transection, before returning to control levels at day 14 (15.9, 3.7, 5.0
and 1.6-fold, p ¼ 3.12E-20, 3.98E-05, 1.07E-06 and .266, respectively).
In contrast, the more upstream alternative pathway activator CFB
was signiﬁcantly downregulated at day 9, before returning to control
levels at day 14 (0.2 and 1.6-fold, p ¼ 1.86E-07 and .296, respec-
tively). Expression levels of C3 and all MAC components were sig-
niﬁcantly elevated at day 1 (p <1E-10, see table), whereas thehy controls)
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